glp-1 drugs medicare to cover weight loss for $50/month Medicare GLP-1 Coverage: $50 Wegovy

Merck presented first-in-human data for two novel therapies in Phase 2 clinical trials

That gap exists for both medications

However, albuminuria is a potent predictor of eGFR decline, so these drugs could delay progression in DKD by reducing albuminuria.99 In a subgroup analysis of the LEADER trial the effect of liraglutide vs

Specifically, patients on exenatide had a mean improvement of 2.3 points in 48 weeks, whereas the control group had a mean decline of 1.7 points, with a difference of 4.3 points (95% CI, 7.1 to 1.6

The cost is also much less expensive than the injectable, potentially making the therapy accessible to more people who would not qualify for insurance to cover it